Diligence memo · auto-generated · as of July 2, 2026
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Exosome Diagnostics, Inc. operates in Biotechnology, based in Waltham.
Sub-sector tags: medical-devices.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Exosome Diagnostics, Inc. has raised $91M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $30M on 2017-06-21.
Most recent recorded round closed around 2017-06-21.
Valuation (modeled)modeled
Provath models Exosome Diagnostics, Inc. at approximately $1.2B (range $61M–$4.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.51× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 9.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 89% of Biotechnology peers (4293 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.